Cellular Senescence Tissue Mapping Center Launched at Yale Cancer Center to Study Human Lymphoid Organs
Newswise – New Haven, Connecticut. – The National Institutes of Health (NIH) awarded a grant to fund research on cell senescence in lymphoid organs at Yale Cancer Center. The $ 6.5 million grant over five years will help generate multi-scale molecular and cellular maps of cellular senescence in primary and secondary human lymphoid organs to improve our understanding of cellular senescence in development, the aging and disease, including cancer.
Cellular senescence is a condition in which cells can no longer divide. This permanent state creates both advantages and disadvantages for the organism in which the cells live. The so-called “senescent” cells are involved in normal biological processes and chronic diseases linked to aging such as cancer and neurodegeneration.
“We are delighted to be working with NIH on this important project because lymphoid organs play a vital role in blood cell production and immune function,” said Rong Fan, PhD, professor of biomedical engineering and pathology, member of the Yale Cancer Center and principal investigator of the study. “The impact of these cells on tissue environments remains poorly understood, making it difficult to develop strategies to target senescent cells to fight aging and cancer or to harness these cells or secreted factors to promote remodeling and repair. normal tissue. “
The NIH award (1U54AG076043-01) is entitled “Yale Tissue Mapping Center (TMC) for Cellular Senescence in Lymphoid Organs.” It is funded by the Cellular Senescence Network (SenNet), which is part of a new NIH Common Fund program consortium established to identify and comprehensively characterize differences in senescent cells in the body, in various human health states and all. throughout life. Yale is one of eight tissue mapping centers for the establishment of the NIH SenNet Consortium.
“This SenNet grant will help accelerate our ability to dissect heterogeneous senescent cells and build the first tissue map of these cells in human lymphatic tissue,” said Stéphanie Halène, MD, PhD, associate professor of medicine (hematology) and head of the hematology department at Yale Cancer Center and Smilow Cancer Hospital and co-principal investigator of the study. “This research could one day provide information on the role of senescent immune cells in development, aging or disease, and uncover new treatments to target cellular senescence to treat a wide range of chronic diseases or cancers that are believed to be difficult to achieve individually. “
The TMC will consist of a core of biological samples led by Halene and Mina Xu, MD, a nucleus of biological analyzes led by Fan and Joseph Craft, MD, and a data analysis component led by Yuval Kluger, PhD.
About Yale Cancer Center and Smilow Cancer Hospital Yale Cancer Center (YCC) is one of 51 National Cancer Institute-designated comprehensive cancer centers nationwide and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive Cancer Centers play a vital role in advancing NCI’s goal of reducing cancer morbidity and mortality through scientific research, cancer prevention and innovative cancer treatments.
# # #